Aging Cell Reversal Trial Stuns FDA

Doctors have cleared the first human patient to test a therapy that reprograms aging cells in the eye, aiming to reverse blindness caused by glaucoma.

Story Snapshot

Life Biosciences, cofounded by Harvard scientist David Sinclair, dosed its first patient in a Phase 1 trial of ER-100.
The Food and Drug Administration (FDA) cleared the study to test safety in patients with open-angle glaucoma and a condition called NAION.
The therapy uses partial epigenetic reprogramming, a method built on a smaller version of the famous Yamanaka genes.
Mouse studies from Sinclair’s lab showed the same approach restored lost vision and kept it stable for nearly a year.

A First-In-Human Trial Targets The Eye

Life Biosciences announced in June 2026 that its Phase 1 trial had dosed its first participant. The company said the treatment, called ER-100, is being tested in people with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, known as NAION. Both conditions damage the optic nerve and can lead to permanent vision loss. Until now, no approved treatment has reversed that kind of damage.

The FDA cleared the company’s application in January 2026, five months before dosing began. Life Biosciences said the study would track safety, tolerability, immune responses, and multiple measures of vision. That last detail matters. Most first-in-human trials only watch for harm. This one also collects data that could hint at whether the therapy actually helps patients see better.

How The Science Works And Where It Came From

ER-100 grew out of years of laboratory work on partial epigenetic reprogramming. The idea borrows from Shinya Yamanaka’s Nobel Prize-winning discovery that four genes can turn adult cells back into stem cells. Sinclair’s team used just three of those genes, known as OSK, and found a way to nudge aged or damaged cells toward a younger state without erasing their identity, according to Sinclair’s own public comments.

Sinclair’s lab published mouse studies showing this approach restored vision lost to glaucoma. In one study, mice given continuous treatment saw their vision fully restored within two months, and it stayed close to healthy levels for eleven months. That kind of durability is rare in early animal research, which is part of why the human trial drew attention before any patient data existed.

What The Company Says This Trial Is Actually Built To Test

Life Biosciences describes the Phase 1 study as enrolling 12 to 18 participants, with dosing that started in 2026 and a registered listing on the government’s clinical trial database. The company has been direct that this is a safety study first. It is not designed to prove the therapy cures blindness. Efficacy measures are included because patients, not healthy volunteers, are enrolled, but the primary goal remains confirming the treatment does not cause harm.

That distinction matters for anyone watching this unfold. A therapy can pass Phase 1 safety checks and still take years, sometimes a decade, before regulators approve it for wide use. Gene and cell therapies for blindness have followed that pattern before, with earlier optic nerve and retinal trials taking years between first dosing and any approved product reaching patients.

The Financial And Reputational Stakes Behind The Science

Life Biosciences closed an $80 million Series D funding round to push ER-100 forward, giving the company a strong financial incentive to highlight every milestone. That is normal for biotech firms chasing breakthrough therapies, and it does not undercut the legitimacy of the FDA clearance or the first dosing. But readers should understand that press releases from a funded company will naturally emphasize progress over uncertainty.

Sinclair has spent years building a public profile around reversing aging, appearing on major podcasts and framing his research as a path toward extending healthy human life. That visibility has made his work a lightning rod for both enthusiasm and criticism in the longevity field. This trial does not resolve that broader debate. It simply tests, in a small group of real patients, whether a lab discovery that worked in mice can be given safely to people.

For now, the facts are narrow but real. A company backed by a well-known Harvard scientist got federal clearance, enrolled patients, and dosed its first participant with a therapy built on cutting-edge cellular reprogramming. The trial will not settle whether blindness can be reversed. It will tell doctors whether the approach is safe enough to keep testing.

Patients with glaucoma and NAION have had few options once nerve damage sets in. Even a safety-only result, if clean, would open the door to larger trials measuring whether vision genuinely improves. That is the milestone worth watching next.